Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and remains one of the leading causes of cancer-related deaths worldwide. Despite advances in targeted therapies and immunotherapy, substantial molecular heterogeneity continues to limit accurate prognostic prediction and effective treatment selection. While metabolic reprogramming is increasingly recognized as a hallmark of HCC, the contribution of lipid droplet-associated genes (LDAGs) to tumor classification and disease progression has remained poorly defined.

In a recent study published in Genes & Diseases, researchers from Chongqing Medical University developed a comprehensive molecular classification framework based on LDAGs to better understand the metabolic diversity of HCC. By integrating transcriptomic and clinical data from 1,834 patients across multiple independent cohorts, the investigators identified biologically distinct HCC subtypes with unique molecular features, clinical outcomes, and therapeutic vulnerabilities.

Using unsupervised consensus clustering of 122 LDAGs, the researchers classified HCC into three molecular subtypes (C1–C3). The C1 subtype represented the most aggressive form of disease, exhibiting advanced tumor stage, increased vascular invasion, enhanced inflammatory infiltration, and significantly poorer overall survival than the other subtypes. Genomic analyses further demonstrated subtype-specific mutation profiles, with TP53 mutations enriched in C1 and CTNNB1 mutations predominating in C3, reinforcing the relationship between lipid metabolism and established oncogenic pathways.

Functional enrichment and pathway analyses revealed distinct metabolic and signaling programs across the three subtypes, highlighting the biological significance of LDAG expression patterns. Drug sensitivity analyses further suggested that tumors belonging to the aggressive C1 subtype may exhibit increased responsiveness to sorafenib, indicating that LDAG-based stratification could help guide precision treatment strategies for patients with advanced HCC.

To identify molecular drivers underlying tumor aggressiveness, the researchers pinpointed five hub genes—PLIN3, SET, CKAP4, RAP1B, and PISD—with PLIN3 emerging as the strongest prognostic biomarker. Experimental validation demonstrated that silencing PLIN3 reduced intracellular lipid accumulation, inhibited HCC cell proliferation and migration, and suppressed tumor growth. Conversely, PLIN3 overexpression promoted aggressive tumor behavior, establishing its critical role in metabolic reprogramming and HCC progression.

Overall, this study establishes LDAG signatures as a robust framework for classifying HCC into clinically meaningful metabolic subtypes. By identifying PLIN3 as both a prognostic biomarker and a potential therapeutic target, the findings provide valuable insights into the metabolic mechanisms driving HCC heterogeneity and offer a foundation for developing more personalized prognostic and therapeutic strategies for liver cancer.

Reference

Title of Original Paper: Lipid droplet-associated gene signatures classify metabolic subtypes and identify PLIN3 as a key driver in hepatocellular carcinoma

Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2026.102067

Funding Information:
The National Key Research and Development Program of China (No. 2022YFA1303600)
The Natural Science Foundation Project of Chongqing, China (No. CSTB2022NSCQ-MSX1277)

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 10.4 | Impact Factor: 14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #